Opened: 18-Feb-2022
Shares Held at Open: 13,631,579
What does ALA do?
Arovella Therapeutics (ASX:ALA) is an early stage biotech research company seeking to develop an off-the-shelf cancer cell therapy treatment - part of the broader field of cancer immunotherapy.
What is the macro theme?
Cancer cell therapy is a burgeoning industry and the next frontier of cancer treatments.
The worldwide spend on cancer therapies is immense and cancer immunotherapy, and cell therapy in particular, hope to unlock new avenues for treatment that are more efficient, more readily available, and ultimately, more successful at treating cancer.
Our Big Bet for ALA
ALA achieves a major breakthrough in cancer immunotherapy, and is acquired by a major pharmaceutical company for multiples of our Initial Entry Price.
Why did we invest in ALA?
New technology to treat cancer with large commercial upside
Cancer cell therapies exist today, but it is in a form that is inefficient, expensive and unreliable - it needs to be individualised to each patient and can cost up to $500K.
ALA's technology aims to produce an ‘off-the-shelf’ treatment that can be produced using healthy, non-patient specific engineered cells, which if successful, will have significant commercial value.
Team with strong track record behind the project
We are impressed with the board and CEO. Chairman Paul Hopper has backed a number of successful ASX-listed biotechs including Imugene (1,160% returns in under 2 years).
Cornerstone ALA investor Merchant Funds Management has an impressive track record in biotech investing.
Licensed technology from top research institutions
The two primary technologies that ALA has licensed both come from top cancer research institutions, the Imperial College in London and MD Anderson Cancer Center.
What do we expect ALA to deliver?
Objective #1: Prepare for Phase-1 clinical trial for treatment #1
Preclinical studies have been completed for ALA’s first treatment (CAR19-iNKT) and we expect ALA to spend the next 12-18 months preparing for a Phase I clinical trial.
This involves completing the manufacturing milestones for the treatment, completing the trial design and securing ethics approval.
Objective #2: Undertake preclinical trials to confirm safety and specificity of treatment #2
ALA will need to confirm that it’s second treatment (DKK1-CAR/mAb), can successfully combine with the iNKT technology and that it does not target healthy cells.
We expect ALA to do this through a preclinical study in mice.
Objective #3: Explore complementary licensing opportunities
ALA’s board has deep knowledge of the cancer immunotherapy market. If a compelling opportunity to licence further tech for their portfolio emerges, we want to see ALA expand on their existing base of technology.
Objective #4: Prepare for Phase-1 clinical trial for Solid Tumour Therapy (with Imugene)
We expect ALA to conduct proof of concept studies and commence IND-enabling studies for ALA-101 + onCARlytics. These include in vivo (test tube) and in vitro (mice) studies that form the basis for an IND application, which is a requirement for ALA to commence a Phase 1 clinical trial. [Added 2-Feb-2023]
What could go wrong?
Early Stage Biotech Risk
There are some standard risks that are associated with early stage biotechs, although the treatment appears effective in mice, this might not translate to humans. Key risks:
Competition risk
There are a large number of companies targeting cancer cell therapies. If a company makes a breakthrough targeting the same disease or using a similar technology to ALA, it may damage the commercial value of ALA’s technology.
Manufacturing risk
As ALA has licensed cutting edge technologies, it may encounter difficulties in the manufacturing process. These could include hurdles found in the manufacturing partner selection process or difficulties scaling the process.
Funding risk
ALA says it is fully funded to prove out the safety profile and get initial manufacturing going through to Phase I trials, but should additional research be needed or manufacturing hurdles encountered, ALA may need to raise more funds before Phase I trials can commence.
Market Risk
We have added this risk to the ALA investment memo going forward.
Biotechs have been out of favour for a long period and this likely impacted ALA’s share price performance, and may impact it in the future.
The market risks for ALA are linked directly to funding risk as capital markets for biotechs remain constrained.
What is our investment plan?
We plan to patiently wait with our investment as the company delivers on the above objectives towards its next major catalyst, which for ALA is the commencement of Phase I clinical trials in the first half of 2023.
We will hold the majority of our position into the Phase I trial and re-assess our investment based on the results. As with all our early stage investments we will look to take some profit in the lead up to the key catalyst event, looking to sell ~20% of our position.
Disclosure: The authors of this article and owners of Next Investors and Finfeed, S3 Consortium Pty Ltd, and associated entities, own 13,631,579 ALA shares. S3 Consortium Pty Ltd has been engaged by ALA to share our commentary on the progress of our investment in ALA over time.
New Deal: ALA can now target lung cancer, pancreatic cancer, gastric cancer
Oct 12, 2023
Oct 12, 2023 |
13 min
Our preclinical biotech Investment, Arovella Therapeutics (ASX: ALA) has just announced that its cancer fighting cell-therapy may now also be able to more effectively target pancreatic, gastric and lung cancer.
ALA edging closer to clinical trials for “off the shelf” cell therapy cancer treatment
Jun 27, 2023
Jun 27, 2023 |
11 min
Another month goes by, and yet another deal in the cancer cell therapy space. We Invested in Arovella Therapeutics (ASX: ALA) to see it develop and ultimately commercialise its own cell therapy cancer therapy treatment.
ALA shows it can scale: Pathway towards an “off the shelf” cancer treatment
Apr 17, 2023
Apr 17, 2023 |
9 min
This morning Arovella Therapeutics (ASX: ALA) released new data indicating its treatment, ALA-101, has the potential to be a novel, ‘off the shelf’ cell therapy to treat leukemias and lymphomas.
We just increased our Investment in ALA - Here’s why
Feb 2, 2023
Feb 2, 2023 |
17 min
A few weeks ago, a child in the UK received a “base edited” cell therapy for leukaemia. The child went into remission (was cured) within four weeks. We also have an investment in the cell therapy space Arovella Therapeutics (ASX:ALA), that could be cheaper, more readily available, and more effective than existing cell therapy treatments.
$1.5M annual cost savings allows ALA to focus on what really matters
Oct 28, 2022
Oct 28, 2022 |
5 min
Arovella Therapeutics (ASX:ALA) announced on Wednesday that it had decided to phase out its legacy operations to fully focus on its CAR iNKT treatment for cancer.
ALA updated investor presentation
Sep 6, 2023
Sep 6, 2023 |
38.9 seconds
In this quick take we take a look at the latest presentation from our biotech Investment Arovella Therapeutics (ASX: ALA).
A boost for ALA’s cancer fighting tech?
Jun 26, 2023
Jun 26, 2023 |
3 min
Today our preclinical biotech Investment, Arovella Therapeutics (ASX: ALA) has revealed that new data from experiments indicate that its iNKT platform technology can be enhanced by another complementary technology.
ALA raises $4M and launches $1M Share Purchase Plan
Jun 7, 2023
Jun 7, 2023 |
2 min
Our cell therapy biotech Investment Arovella Therapeutics Ltd (ASX:ALA) just raised $4M in capital at 4.5c per share.
ALA’s laser-like focus on INkT cell therapy; costs cut
May 1, 2023
May 1, 2023 |
1 min
Our biotech Investment Arovella Therapeutics Ltd (ASX:ALA) today announced that the closure of its Perth OroMist R&D facility is complete — cutting company expenditure by around $1.5M per year.
Arovella to present on tomorrow (4/04/2023)
Apr 3, 2023
Apr 3, 2023 |
2 min
Our preclinical biotech Investment, Arovella Therapeutics (ASX:ALA), will be presenting an “Explanatory Webinar” tomorrow - which should give us a great look at how the company’s allogeneic iNKT Cell Platform works.
Next Cap Raise - for Sophisticated Investors
Oct 14, 2023
Oct 14, 2023 |
9 min
After years of preparation, our investment Noble Helium (ASX: NHE) nears its crucial drilling phase for a monumental helium project in Tanzania. Meanwhile we have launched our new "Next Cap Raise" mailing list which offers exclusive investment opportunities for certified s708 sophisticated investors.
Investing in Early-Stage Biotechs and the Drill Race is on...
Sep 9, 2023
Sep 9, 2023 |
11 min
In this Weekender, we look at the high-risk, high-reward landscape of biotech investing, early-stage companies offer outsized returns on successful clinical trials, aligning perfectly with our investment strategy and providing a unique opportunity to contribute to groundbreaking advancements in medical science.
New Investment Coming and winners in a down market
Sep 2, 2023
Sep 2, 2023 |
11 min
In this Weekender, we announce an upcoming portfolio addition on Monday at 10am AEST (4th September 2023) and look at the current stage the small caps market is on the business cycle.
Why we invest in Oil & Gas and Precious Metals
Feb 21, 2022
Feb 21, 2022 |
17 min
Across our portfolios we have investments in battery metals, oil & gas, precious metals, medicinal cannabis, early stage tech, green energy, growth stocks and new energy materials.
